Expertise in
1
conditions

Michal M. Lotem

Jerusalem, JM, IL 
Expertise in
1
conditions
Jerusalem, JM, IL 

Overview

Michal Lotem practices practicing medicine in Jerusalem, Israel.

Lotem is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Melanoma, Melasma, Kaposi Sarcoma, and Lung Cancer.

They are actively involved in clinical research, co-authoring 86 peer reviewed articles and participating in 3 clinical trials.

Locations

Jerusalem, JM, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

PROPHETIC - Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
PROPHETIC - Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Other
A Phase I/IIa, Multicentre, Two Parts, Open-Label Study Designed to Evaluate the Safety and Tolerability of Escalating Doses of AGI-134 in Unresectable/Metastatic Solid Tumours
A Phase I/IIa, Multicentre, Two Parts, Open-Label Study Designed to Evaluate the Safety and Tolerability of Escalating Doses of AGI-134 in Unresectable/Metastatic Solid Tumours
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101)
A Phase 1b Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors (ILLUMINATE-101)
Enrollment Status: Completed
Publish Date: February 11, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 2 Less Clinical Trials

86 Total Publications

UV irradiation drives lineage-specific MITF-mediated transcription of PD-L1 to confer immune tolerance to UV-mutated melanocytes.
UV irradiation drives lineage-specific MITF-mediated transcription of PD-L1 to confer immune tolerance to UV-mutated melanocytes.
Journal: Immunity
Published: September 03, 2026

Frequently Asked Questions about Michal M. Lotem

Is Michal M. Lotem a top-rated expert for Melanoma?

MediFind is an objective health platform that identifies experts based on real-world data. Michal M. Lotem is classified as an Distinguished expert for Melanoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Michal M. Lotem participate in research or clinical trials?

Yes. Michal M. Lotem has published 86 articles and abstracts on conditions like Melanoma. You can view a list of Michal M. Lotem's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Lotem's expertise for a condition
ConditionClose
      View All 17 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile